Maladies peptiques [Progress in 2008 for acid related diseases]

Détails

ID Serval
serval:BIB_46E5D698B7F2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Maladies peptiques [Progress in 2008 for acid related diseases]
Périodique
Revue Médicale Suisse
Auteur(s)
Jornod P., Vouillamoz D., Viani F., Nichita C., Dorta G.
ISSN
1660-9379
Statut éditorial
Publié
Date de publication
2009
Volume
5
Numéro
187
Pages
167-175
Langue
français
Résumé
The treatment of reflux disease did not change in the review period. PPI therapy remains the first line treatment and surgery the second line approach. Endoscopic anti-reflux procedures should be only performed in controlled studies. Beside the classic triple therapy, sequential treatment of Helicobacter pylori infection can today be considered as a first line therapy. PPI are effective in the prevention of gastroduodenal lesions and in the treatment of dyspeptic symptoms induced by NSAIDs treatment. Only patients younger then 65 years and without any risk factors do not need a preventive PPI prescription during classic NSAIDS treatment.
Mots-clé
Anti-Ulcer Agents, Digestive System Surgical Procedures, Gastroesophageal Reflux, Helicobacter Infections, Humans, Proton Pump Inhibitors
Pubmed
Création de la notice
17/04/2009 19:08
Dernière modification de la notice
03/03/2018 16:48
Données d'usage